A new drug to treat Stargardt disease has helped to slow down the progression of the condition in some patients, according to the latest results of a phase two clinical trial.
Pharmaceutical company Belite Bio is testing a new orally administered tablet for Stargardt and late stage dry age-related macular degeneration (AMD).
Read more below from the Macular Society website.
Link to Macular Society Website
One Vision Blog 